New TB vaccines: Is there a requirement for CD8+ T cells?

Journal of Clinical Investigation

Volumn 117, Issue 8, 2007, Pages 2092-2094

  Boom, W Henry ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; EARLY SECRETORY ANTIGENIC TARGET 6; HYBRID PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MYCOBACTERIUM ANTIGEN; PROTEIN 72F; PROTEIN 85B; T LYMPHOCYTE RECEPTOR DELTA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; APOPTOSIS; BCG VACCINATION; CD8+ T LYMPHOCYTE; CROSS REACTION; DNA MODIFICATION; DRUG EFFECT; DRUG EFFICACY; HOST CELL; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MACROPHAGE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS;

ADENOSINE TRIPHOSPHATASES; ANIMALS; BACTERIAL PROTEINS; CELL LINE; GENE DELETION; GUINEA PIGS; HUMANS; MACROPHAGES; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, INBRED BALB C; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; SUPEROXIDE DISMUTASE; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 34547700637     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI32933     Document Type: Review

References (23)

1. [Anonymous]. 2007. Global tuberculosis control - surveillance, planning, financing. Report of a WHO expert committee. WHO. Geneva, Switzerland. http://www.who.int/tb/publications/global_report/2007/en/index.html.
2. Colditz, G.A., et al. 1995. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics. 96:29-35.
3. Colditz, G.A., et al. 1994. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA. 271:698-702.
4. Rodrigues, L.C., et al. 2005. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet. 366:1290-1295.
5. Cole, S.T. 2002. Comparative and functional genomics of the Mycobacterium tuberculosis complex. Microbiology. 148:2919-2928.
6. Hingley-Wilson, S.M., Sambandamurthy, V.K., and Jacobs, W.R., Jr. 2003. Survival perspectives from the world's most successful pathogen, Mycobacterium tuberculosis. Nat. Immunol. 4:949-955.
7. Hinchey, J., et al. 2007. Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis. J. Clin. Invest. 117:2279-2288. doi:10.1172/JCI31947.
8. Braunstein, M., et al. 2003. SecA2 functions in the secretion of superoxide dismutase A and in the virulence of Mycobacterium tuberculosis. Mol. Microbiol. 48:453-464.
9. Boom, W.H., et al. 2003. Human immunity to M. tuberculosis: T cell subsets and antigen processing. Tuberculosis. (Edinb.). 83:98-106.
10. Sud, D., et al. 2006. Contribution of CD8+ T cells to control of Mycobacterium tuberculosis infection. J. Immunol. 176:4296-4314.
11. Ramachandra, L., et al. 1999. Phagocytic antigen processing and effects of microbial products on antigen processing and T-cell responses. Immunol. Rev. 168:217-239.
12. Rock, K.L. 2006. Exiting the outside world for cross-presentation. Immunity. 25:523-525.
13. Canaday, D.H., et al. 1999. Activation of human CD8+ alpha beta TCR+ cells by Mycobacterium tuberculosis via an alternate class I MHC antigen-processing pathway. J. Immunol. 162:372-379.
14. Russell, D.G. 2007. Who puts the tubercle in tuberculosis? Nat. Rev. Microbiol. 5:39-47.
15. Winau, F., et al. 2006. Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis. Immunity. 24:105-117.
16. Hogquist, K.A., et al. 1994. T cell receptor antagonist peptides induce positive selection. Cell. 76:17-27.
17. Flynn, J.L. 2006. Lessons from experimental Mycobacterium tuberculosis infections. Microbes Infect. 8:1179-1188.
18. Kaufmann, S.H., Baumann, S., and Nasser Eddine, A. 2006. Exploiting immunology and molecular genetics for rational vaccine design against tuberculosis. Int. J. Tuberc. Lung Dis. 10:1068-1079.
19. Olsen, A.W., et al. 2004. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect. Immun. 72:6148-6150.
20. Skeiky, Y.A., et al. 2004. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J. Immunol. 172:7618-7628.
21. McShane, H., et al. 2004. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat. Med. 10:1240-1244.
22. Grode, L., et al. 2005. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. J. Clin. Invest. 115:2472-2479. doi:10.1172/JCI24617.
23. Horwitz, M.A., and Harth, G. 2003. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect. Immun. 71:1672-1679.